Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "ASA"

521 News Found

Bayer’s pharma growth strategy progressing well as pipeline advances
News | January 15, 2025

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid


JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
News | January 09, 2025

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)


Granules India FDA approval for ADHD treatment
Drug Approval | December 17, 2024

Granules India FDA approval for ADHD treatment


Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Clinical Trials | December 17, 2024

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion


Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'
Healthcare | December 16, 2024

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%


Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
News | December 09, 2024

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape


Granules' net zero commitment approved by SBTi
News | November 28, 2024

Granules' net zero commitment approved by SBTi

In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030


CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance
Healthcare | November 26, 2024

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions


Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
News | November 13, 2024

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds